|
|
|
|
|
 |
Global Presence |
|
|
|
|
|
|
Granules USA Inc. is a 100 percent owned US-based subsidiary that provides existing and prospective customers in US with a direct interface.
In 2005-06, over half of our sales were generated in the US - the world's largest pharmaceutical market, valued at an estimated $230 billion. With FDA and TGA approved manufacturing facilities, we have had a solid platform for growth in this key region.
Granules Pharmaceuticals operations in the United States are conducted through its fully owned subsidiary - Granules Inc, which was incorporated in 1987 and has been operating in the US market for over 19 years.
Mr.Jonathan Berlent
President
Granules USA INC.
111 HOWARD BLVD
SUITE 101, MT.ARLINGTON
NJ 07856
Tele 973 - 770- 3181
Contacts in the United States - jberlent@granulesindia.com |
|
|
|
|
|
|
|
GIL has major market share in the candian market for its OTC related business. As a part of the forward integration strategy, the company's present focus is to offer combination products in the OTC segment,
both as PFIs and finished dosages. GIL has already proved its capabilities with the Candian TPD approval and strategic tie-ups with major generic companies on R & D projects which would be taken on a commercial level once the registrations are in place.
Contacts in the Canada - bnrprasad@granulesindia.com |
|
|
|
|
|
|
|
|
For GIL, Latin America has been an ongoing investment. In 2005-06, over 22% of our sales were generated in Latin America, which is one of the fastest growing markets in the world Valued at US$24 billion. Today GIL has increased its market share due to the increase in the awareness of market and adoption of competitive
marketing strategy and value added technical support. The company currently has strong presence in four major markets- Colombia, Chile,Brazil and Mexico and is continously expanding its presence in these key markets and other markets in the region.
Mr.Stefan Lohle Corredor,
President
Calle 50n. 51-24 of. 1102
MEDELLIN - COLOMBIA,
tele 57.4 - 511.1969 / 4307 - 512.2403,
fax 57.4 - 231.0272.,
Contacts in Latin America - slohle@granulesindia.com |
|
|
|
|
|
|
|
|
In this region,GIL has a powerful presence in three major markets - Germany, UK and France. In the past few years, the main drive of the company's growth in this market has been its API & PFI business. With the increase in the formulations business opportunities in Europe, GIL's main focus now will be on the finished
formulation contacts with the major pharmaceutical giants.
Mr.Michael Frude
President
Spancers Cottage
Newton St Loe
Bath
BA2 9BT
United Kingdom
Tele +44 (0) 225872334
Mobile +44 (0) 7823779142
Contacts in Europe - mfrude@granulesindia.com |
|
|
|
|
|
|
|
|
At present GIL operates out of India and one of GIL's main challenges in the next few years will be to deepen an already strong business footprint in the Asia Pacific region. The company has a particularly powerful presence in three major markets - Indonesia, Australia and the Middle East.
Contact in A.Pac - pathi@granulesindia.com |
|
|
|
|
|
|
|
|
|
|
|
